trial

An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia

NCTId NCT05643170
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment 4 (actual)
Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Primary completion 2023-03-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
4 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2022-11-08
Primary completion
2023-03-01
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Xanomeline-trospium (Cobenfy)

Sponsors

Karuna Therapeutics, Inc., a Bristol Myers Squibb companyLead Sponsor

Sites

5 total
Atlanta, United StatesLouisville, United StatesColumbus, United StatesRock Hill, United StatesSt. George, United States

Linked catalysts

1
An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, — primary completion2023-03-01

Facts & assertions

4 sourced
Enrollment
4
Phase
PHASE3
Primary Completion Date
2023-03-01
Status
TERMINATED
relationships
The graph out of here
drug
Xanomeline-trospium (Cobenfy)
drug
lead_sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
company
indication
Schizophrenia
indication
Schizophrenia
indication